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Abstract: Triamcinolone is a corticosteroid that is used to treat many ophthalmic diseases. 
Recently, its use has been advocated to aid in visualization of transparent tissue in ophthalmic 
surgery. It can be used in anterior segment surgery to help manage vitreous loss during compli-
cated cataract surgery. It has been used to visualize the posterior cortical vitreous during pars 
plana vitrectomy. In addition, it can be useful in the visualization and peeling of the internal 
limiting membrane. Triamcinolone has been advocated in surgical repair of proliferative vit-
reoretinopathy both for its visualizing properties and its anti-inﬂ  ammatory properties. Overall, 
triamcinolone use in surgery is safe with low incidence of complications including elevated 
intraocular pressure, cataract and endophthalmitis.
Keywords: cataract surgery, chromovitrectomy, epiretinal membrane, internal limiting mem-
brane, triamcinolone acetonide, vitrectomy
Triamcinolone acetonide (TA) is a synthetic corticosteroid that has many uses is 
medicine. It can be administered in a multitude of ways including orally, parenterally, 
topically, by inhalation and intraocularly. While TA has been used in the treatment of 
ophthalmic diseases for many decades, it has recently been advocated as an adjuvant 
in ophthalmic surgery. The main use of TA in ophthalmic surgery is to aid in visual-
ization of transparent membranes within the eye.
Triamcinolone is a corticosteroid that is well known for its anti-inﬂ  ammatory, 
anti-permeability and anti-ﬁ  brotic properties, which justiﬁ  es its use in inﬂ  ammatory 
and vascular ophthalmic diseases (Floman and Zor 1977; Lewis et al 1986). However, 
recent evidence suggests that this water-insoluble steroid is also useful for ophthalmic 
surgery because it aids in visualization of ophthalmic structures, such as vitreous and 
internal limiting membrane. This property is heavily reliant upon the insoluble nature of 
the white crystals and the integration of these crystals into loosely organized collagen 
matrices. These crystals are thought to be interwoven into the collagen bundles of 
the vitreous (Peyman et al 2000; Enaida et al 2003). An extension of this mechanism 
is thought to be responsible for the staining of the superﬁ  cial portions of an internal 
limiting membrane (ILM) and an epiretinal membrane (ERM). Studies have shown by 
electron microscopy that after manual vitreous detachment a small layer of cells and 
collagen ﬁ  bers remain attached to the retina. This residual material may be responsible 
for the integration of TA crystals, which allow the visualization of the ILM and ERM 
(Shah et al 2004; Horio et al 2005; Tognetto et al 2005). Since no known biochemical 
reaction occurs to cause this visualization, the TA can be washed away with careful 
and continuous irrigation or aspiration after instillation in the eye.
Intraocular TA can be prepared in several ways. Triesence® (Alcon, Fort Worth, TX, 
USA) is a preservative-free preparation of TA that is approved by the FDA for intraocular 
use including use for vitreous visualization in intraocular surgery. It comes as a 1 mL vial Clinical Ophthalmology 2008:2(4) 892
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containing a suspension of  TA with concentration of 40 mg/mL. 
Recommended dosing is 1–4 mg (25–100 μL) administered 
intravitreally. Trivaris® (Allergan, Irvine, CA, USA) was 
recently approved as a preservative-free gel for intravitreal 
injection. It comes in a single-use syringe with 8 mg (80 mg/mL) 
of   TA suspension. As an off-label use, Kenalog® (Bristol-
Myers Squibb, Peapack, NJ, USA) can be administered for 
the same indication. Kenalog® contains benzyl alcohol as a 
preservative; many retinal surgeons prefer to use non-preserved 
Kenalog®, after a compounding pharmacy removes the preser-
vative (Bakri et al 2005). The standard concentration of this 
preparation is 40 mg/mL. The triamcinolone is often diluted 
with balanced salt solution at about 1:4 before instilling in the 
eye during vitrectomy.
Chromovitrectomy is the use of chemicals to stain 
semitransparent preretinal structures as an aid in successful 
vitreoretinal surgery. Several different dyes have been tried, 
and only a few substances remain as commonplace in sur-
gery including indocyanine green (ICG), trypan blue (TB) 
and recently TA. ICG is a water-soluble dye that is used in 
vitrectomy because it binds to type IV collagen, allowing 
visualization of the ILM. ICG is well known for its use in 
retinochoroidal angiography. TB is also a water-soluble 
dye, but it has a high afﬁ  nity for cellular components, which 
allows visualization of an ERM (Rodrigues et al 2005). As 
discussed above, TA intertwines itself in collagen matrices 
and will therefore coat both an ERM and ILM (Shah et al 
2004; Horio et al 2005; Tognetto et al 2005). When com-
paring TA and ICG, there are many reasons to favor TA. 
First, unlike ICG, which requires a speciﬁ  c dilution ratio, 
TA does not require any preparation in the operating room. 
ICG, unlike TA, cannot be completely removed from all the 
tissues in the eye after it is used, as it stains the tissue. Tri-
amcinolone coats the tissue. TA is less expensive than ICG 
(US $25 per dose versus US $135 per dose). Multiple adverse 
effects have been linked to ICG, including retinal pigment 
epithelial defects, optic nerve damage, long-term retinal 
staining, and photosensitivity to retinal laser after adminis-
tration (Rodrigues et al 2005; Gandorfer et al 2003). Some 
studies have indicated that visual outcomes are worse after 
ICG-assisted ILM peeling (Rodrigues et al 2005). However, 
as described earlier, ICG stains the ILM directly, unlike TA, 
which does not differentiate between ILM and ERM because 
it simply coats the surface. TB possibly has some retinal 
toxic effects described in animal studies (Veckeneer et al 
2001). Since TA simply integrates into the collagen matrix 
it can be removed with continuous aspiration or irrigation. 
However, unlike ICG or TB, TA can be repeated until desired 
visualization is achieved (Shah et al 2004; Horio et al 2005; 
Rodrigues et al 2005; Kampougeris et al 2007).
Surgical uses
During cataract surgery, posterior capsule violation and 
prolapse of vitreous body are troublesome complications. 
Unless effectively treated vitreous loss may be a harbinger 
to poor intraoperative or post-operative outcomes from 
sequelae such as retinal detachment and macular edema. 
The incidence of these complications can be lessened 
with meticulous removal of all vitreous tissue within the 
anterior chamber (Arbisser et al 2006; Chang et al 2006). 
Localization of vitreous and knowing when the anterior 
vitrectomy is complete are difﬁ  cult because of the invisible 
nature of vitreous. Burk et al (2003) ﬁ  rst described the use 
of TA to aid in the visualization of lost vitreous. When TA 
suspension is irrigated into an anterior chamber containing 
vitreous, the white crystals mix into the matrix effectively 
highlighting the vitreous boundaries. Effective visualization 
of anterior chamber vitreous allows for thorough anterior 
vitrectomy and allows the surgeon to avoid maneuvers 
that increase vitreous traction. In addition, it also offers 
a comfortable endpoint to the anterior vitrectomy (Burk 
et al 2003; Arbisser et al 2006; Chang et al 2006; Yamakiri 
et al 2006).
Pars plana vitrectomy (PPV) is a common vitreoretinal 
procedure used in the treatment of multiple conditions 
including vitreomacular traction syndrome, macular hole, 
epiretinal membranes, advanced diabetic retinopathy, and 
retinal detachment (RD) repair. During PPV, thorough 
removal of the vitreous and the posterior hyaloid mem-
brane is an important surgical goal. Vitreoretinal adhesion 
has been suspected in the evolution of complicated retinal 
detachments and severe diabetic retinopathy (Peyman et al 
2000; Sakamoto et al 2002; Sonoda et al 2004; Doi et al 
2005; Matsumo et al 2007). During vitrectomy a posterior 
vitreous separation is induced, which may be difﬁ  cult in 
some patients, especially diabetics and young patients. 
Post-operative residual hyaloid may provide scaffolding 
for ﬁ  brovascular proliferation in proliferative diabetic 
retinopathy or may provide a foundation of traction, which 
may cause or exacerbate conditions like macular holes or 
vitreomacular traction syndrome (Sonoda et al 2004; Doi 
et al 2005). Meticulous removal of minute amounts of vit-
reous and hyaloid membrane requires patience and careful 
observation, but if the vitreous boundaries could be high-
lighted this process could be more efﬁ  cient and effective 
(Figures 1 and 2). Peyman et al (2000) were the ﬁ  rst to Clinical Ophthalmology 2008:2(4) 893
Triamcinolone during vitrectomy
Figure 1 Injection of triamcinolone during vitrectomy.
Figure 2 Triamcinolone staining of residual vitreous cortex.Clinical Ophthalmology 2008:2(4) 894
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describe the use of TA to aid in vitreous visualization. 
It was noted that when TA is injected into the vitreous 
cavity the crystals become trapped in the vitreous gel and 
the suspension allows for good contrast between the whit-
ened vitreous and the post-hyaloid space which harbors a 
free-ﬂ  oating suspension of TA particles. Because of better 
visualization, TA assistance in PPV has been shown to help 
surgeons perform a more thorough removal of vitreous and 
posterior hyaloid.
In addition to a comprehensive PPV, removal of the ILM 
is used as an adjunct in vitreoretinal surgery in the repair of 
macular holes, cellophane maculopathy, and macular edema. 
It is thought that peeling of the internal limiting membrane 
reduces tangential retinal traction and improves macular hole 
closure rate (Doi et al 2005). Removal of this transparent thin 
membrane proves difﬁ  cult even for experienced surgeons. 
As described above, dyes have been utilized to aid in the 
visualization of the ILM and ERM. Injection of TA allows 
delineation of an ILM and ERM secondary to integration 
of the crystals into its superﬁ  cial collagen ﬁ  brils (Figure 3) 
(Horio et al 2005). TA provides contrast between the high-
lighted ILM and ERM and those areas that have already 
been delaminated because the TA will not stain exposed 
retina (Shah et al 2004, 2005; Fraser et al 2003; Kimura et al 
2004; Tognetto et al 2005). If TA is utilized in the vitrectomy 
stage of the procedure, it can be reinjected for ILM or ERM 
visualization and the surgeon may require reinjection if the 
TA is washed away by irrigation or aspiration. However, 
because of the TA crystals water insolubility, there have 
been some concerns with residual TA affecting macular hole 
closure rates, but visual outcomes are the same or better after 
the procedure (Karacorlu et al 2005; Kumagai et al 2007; 
Hikichi et al 2008).
One of the most common reasons for failure of RD repair 
is proliferative vitreoretinopathy (PVR). PVR is proliferation 
and subsequent contraction of a ﬁ  brous nonvascular epiretinal 
membrane at the vitreoretinal interface generally stimulated 
by rhegmatogenous retinal detachment (Girard et al 1994; 
Furino et al 2003). Subsequent surgery for RD with PVR is 
tedious and problematic as it is generally associated with 
poor anatomic and visual outcomes. One of the established 
treatments for PVR is PPV with the surgical goal to remove 
any residual vitreous and tractional ERMs. Removal of the 
ERM is thought to be the most important factor inﬂ  uencing 
clinical outcomes after surgery for PVR (Aaberg 1988; 
Abrams et al 1997; Girard et al 2004; Ueno et al 2007). 
Figure 3 Enhanced visibility of epiretinal membrane with triamcinolone.Clinical Ophthalmology 2008:2(4) 895
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As described previously, remaining posterior hyaloid face 
and ERMs are transparent making their removal tedious. TA 
has been used as an adjunct in visualization and subsequent 
surgical removal of these membranes and the remaining 
vitreous cortex. Previous studies have shown that intravitreal 
injection of corticosteroids, including TA, can be used in the 
treatment and prevention of further ﬁ  brous growth (Jonas 
et al 2000; Girard et al 2004). The anti-inﬂ  ammatory and 
anti-ﬁ  brotic effects of TA may further advocate its use with 
this type of surgery. Several studies have advocated the use 
of TA in surgery for PVR with good success rates (Furino 
et al 2003; Ueno et al 2007). Sonada et al (2003) supported 
the use of TA assistance in PVR treatment associated with 
refractory uveitis with good results. Because of other surgical 
techniques used in the treatment of PVR, it is important to 
remember that silicone oil protracts the absorption of TA 
(Girard et al 2004).
Perﬂ  uorcarbon (PFC) liquid has been widely used in 
combination with PPV. However, because of its retinotoxic 
properties if left in the eye long term, it must be completely 
removed during vitrectomy. Because PFC is invisible, 
residual bubbles are commonly found after surgery. Hirata 
et al (2005) showed in vivo and in vitro that PFC adsorbs the 
TA and highlights residual PFC for easier removal.
Intravitreal TA has been used for its anti-inﬂ  ammatory 
properties for many decades in the treatment of various 
intraocular diseases. It is well known for its anti-angiogenic 
and anti-ﬁ  brotic properties, which can have a beneﬁ  cial 
effect in the treatment of conditions commonly treated with 
intraocular surgery (Kampougeris et al 2007). One study 
objectively showed a decrease in postoperative blood-ocular 
barrier breakdown after TA-assisted PPV, especially for 
diabetic macular edema (Sakamoto et al 2002).
A low incidence of adverse outcomes has been found 
with TA-assisted intraocular surgery. Recent studies 
showed a decrease in intraoperative complications including 
retinal detachment and retinal breaks (Yamakiri et al 2007). 
However, 1-year data showed no difference in visual acuity, 
need for additional surgeries, and adverse events between 
TA-assisted PPV and conventional PPV (Yamakiri et al 
2008). As shown with previous studies of intravitreal triam-
cinolone, the more common complications include cataract 
formation and elevated intraocular pressure. However, the 
incidence of these complications are less than expected 
(Enaida et al 2003; Sakamoto et al 2002; Chang et al 2006; 
Kampougeris et al 2007; Kumagai et al 2007; Ueno et al 
2007; Hikichi et al 2008). Several studies have shown 
residual retinal TA after PPV. While no direct retinotoxic 
effects have been shown with TA, there is still concern 
about toxic effects of the TA’s vehicle (Kampougeris et al 
2007). Other studies have been concerned where the TA 
crystals anatomically reside if they are left behind and have 
shown no long term visual or anatomic consequence even 
if left in within the fovea (Takeuchi et al 2003; Fukukita 
et al 2007; Hikichi et al 2008). Finally, intravitreal TA in 
nonvitrectomized eyes is associated with a low incidence of 
endophthalmitis and the same would be expected after TA-
assisted vitrectomy. It also may mask many of the common 
clinical signs of endophthalmitis after intraocular surgery 
(Yamashita et al 2004). Despite these complications, TA 
is considered safe by most clinicians for assistance with 
intraocular surgery.
Triamcinolone acetate has been used in ocular therapeu-
tics and its indications are expanding. Because it integrates 
into collagen matrices, it has been used to help delineate vitre-
ous, internal limiting membranes, and epiretinal membranes. 
This has been useful in treatment of complicated cataract 
surgery, pars plana vitrectomy, and macular surgery. With 
a low incidence of adverse events, it is regarded as safe for 
use in assistance with intraocular surgery.
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